Dog Lymphoma: Welfare Through Treatment Decisions

Lymphoma is one of the most common cancers in dogs, and treatment decisions profoundly affect quality of life during and after therapy.

Key Facts

Lymphoma accounts for approximately 7-14% of all canine cancers
Multicentric lymphoma (affecting multiple lymph nodes) is the most common form
Golden Retrievers, Boxers, and Bulldogs are among the highest-risk breeds
CHOP chemotherapy achieves remission in 70-90% of dogs with multicentric lymphoma
Median survival with treatment is 12-14 months; without treatment, weeks to months
Prednisolone alone can provide temporary relief but shortens response to subsequent chemo

Welfare Considerations

Lymphoma treatment decisions require careful welfare assessment: chemotherapy in dogs typically causes fewer and milder side effects than in humans, with most dogs maintaining good quality of life during treatment. However, the commitment is significant - weekly hospital visits, potential side effects including nausea and reduced immunity, and financial cost. Quality of life during remission is generally excellent, making treatment a welfare-positive choice for many dogs. The key welfare issue is avoiding prolonged suffering in non-responsive disease; clear benchmarks for reassessing and transitioning to palliative care should be established at the outset.

What You Can Do

Consult a veterinary oncologist for staging and treatment planning
Discuss quality-of-life benchmarks and decision points before starting treatment
Monitor appetite, energy, and enjoyment of daily activities as welfare indicators
Ask about anti-nausea medication and supportive care to minimize side effects
Consider a referral centre for CHOP protocol to maximize remission rates
Establish a clear plan for palliative care transition if remission is not achieved